ATLASATLAS fair value
ATLAS has no fair value for this stock today.
Genomictree (228760.KQ)
Genomictree stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · KOSDAQ · South Korea
₩9,730▲ +1.88%
Prices as of Oct 27, 2026 · KRW
Chance of rising in 1 month
46%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on Genomictree in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On Genomictree
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives Genomictree a 46% chance of finishing higher a month from now (21 trading sessions) than today: close to a coin flip.
In half of the simulated outcomes the price ends between ₩8,371 and ₩10,897; in 9 out of 10, between ₩6,626 and ₩13,767. Estimated annual volatility is 79%.
Price, last 12 months (weekly close)
Key numbers
- Market cap
- ₩217B
- Market cap (USD)
- $164M
- 52-week high
- ₩33,300
- 52-week low
- ₩8,790
- Revenue (12 months)
- ₩2.9B
- Operating margin
- -313.9%
- Net margin
- 0.0%
- Beta
- 0.09
What this means
ATLAS does not publish a fair value for 228760.KQ right now, but it does show its odds of rising: close to a coin flip.
Over the last 52 weeks 228760.KQ has traded between ₩8,790 and ₩33,300. Today it is 70.8% below that high and 11% above its low.
Its beta is 0.09: it tends to move less than the market.
About the company
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases.
Want to see everything about Genomictree?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does Genomictree do?
Genomictree Inc., a biomarker-based molecular diagnostics company, develops and commercializes molecular diagnostic products for the detection of cancer and various infectious diseases.
What is the chance 228760.KQ goes up next month?
46%: close to a coin flip. In half of the simulated outcomes, 228760.KQ ends the month between ₩8,371 and ₩10,897.
How big is Genomictree and what is its P/E ratio?
Genomictree's market capitalization is ₩217B. We do not show a P/E because it has no positive earnings to base one on.
How volatile is 228760.KQ?
ATLAS estimates annual volatility at 79%. In a typical month, half of the outcomes end between ₩8,371 and ₩10,897.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer